NCT07320456Not yet recruitingPhase 2
A Clinical Trial of Longqi Jiangzhi Decoction Against Non-alcoholic Fatty Liver Disease
Effect of Longqi Jiangzhi Decoction on Non-alcoholic Fatty Liver Disease: a Randomized Clinical Trial
Source: ClinicalTrials.gov · Last updated 6 Jan 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn if Longqi Jiangzhi decoction works to treat non-alcoholic fatty liver disease in adults. It will also learn about the safety of drug Longqi Jiangzhi decoction. Researchers will compare drug Longqi Jiangzhi decoction to a placebo (a look-alike substance that contains no drug) to see if drug Longqi Jiangzhi decoction works to treat non-alcoholic fatty liver disease. Participants will: Take drug Longqi Jiangzhi decoction or a placebo every day for eight weeks Keep a record of their symptoms and the degree of hepatic steatosis before and after the treatment.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 7 Dec 2025
- Start date
- 29 Dec 2025
- Primary completion date
- 31 May 2026
- Lead sponsor
- Shanghai Municipal Hospital of Traditional Chinese Medicine
- Diseases
- Fatty liver disease (MASLD/MASH)
- NCT number
- NCT07320456
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 80
- From 29 Dec 2025 to the primary completion date, 31 May 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Has liver steatosis due to other definitive causes, such as alcoholic liver disease, drug-induced liver injury, viral hepatitis infections (e.g., hepatitis B, hepatitis C, etc.);
- Has other serious liver diseases, such as autoimmune liver diseases, primary biliary cholangitis, Wilson's disease, etc.;
- Has other serious systemic diseases, such as malignant tumors, active systemic lupus erythematosus, etc.;
- Known allergy or intolerance to any component of the study medication;
- Has severe mental illness or behavioral disorders that may affect adherence to the study protocol;
- Other conditions that the researcher considers unsuitable for participation in this study.
Lab values
- Has severe dysfunction of major organs such as the heart, kidneys, lungs, etc., such as severe heart failure (NYHA functional classification III or above), renal failure (glomerular filtration rate eGFR \< 30 mL/min/1.73m²), acute exacerbation of chronic obstructive pulmonary disease, etc.;
Age
- Pregnant women, lactating women, or women of childbearing age who refuse to use effective contraception during the trial;
Other
- Has participated in another clinical trial within the last three months;
Who the study is looking for
- Age 18-50 years, both genders eligible;
- Meets the diagnostic criteria for NAFLD;
- Meets the diagnostic criteria for Traditional Chinese Medicine Spleen Deficiency and Damp-Heat Syndrome;
- Has significant risk factors: CAP≥238dB/m, Body Mass Index (BMI) ≥23 kg/m²;
- Has not received any anti-NAFLD medication treatment in the past month;
- Normal major organ function, including heart, kidney, and liver functions, specifically: no significant abnormalities on electrocardiogram; normal serum creatinine and urea nitrogen; normal serum bilirubin and albumin levels;
- Has sufficient cognitive and understanding abilities to comprehend the study content and its potential risks and benefits;
- Voluntarily participates in the study and signs an informed consent form.
Age in the registry: 18 years to 50 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.